FLGT vs MYGN
FLGT: Fulgent Genetics is a diagnostic laboratory that leverages proprietary technology to provide accessible, affordable, and actionable genetic testing for rare diseases, cancer, and reproductive health. MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions.
Side-by-side fundamentals
| Metric | FLGT | MYGN | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $20.13 | $5.57 | |
| Market cap | $554M | $533M | |
| Net margin FY2025, SEC XBRL | -18.8% | -44.4% | FLGT higher |
| Gross margin FY2025, SEC XBRL | +40.6% | +69.9% | MYGN higher |
| Operating margin FY2025, SEC XBRL | -28.2% | -47.0% | FLGT higher |
| ROE FY2025, SEC XBRL | -5.4% | -99.4% | FLGT higher |
| ROA FY2025, SEC XBRL | -5.0% | -51.8% | FLGT higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.40 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +13.8% | -1.6% | FLGT higher |
| Revenue CAGR (3y) SEC XBRL | -19.5% | +6.7% | MYGN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.70 | 1.13 | |
| 1-year return as of 2026-10-21 close | -16.0% | -30.9% | FLGT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.